Multiparametric Imaging for Analysis of MVNT (Multinodular and Vacuolating Neuronal Tumor)

NCT04103190 | Completed

• 1 other identifier: ALR_2019_4
• Study Type: observational
• Target: 71
• Locations: 1 country
• Sites: 7

Brief Summary

Differential diagnoses of MVNT include DNT (dysembryoplastic neuroepithelial tumor), low-grade gliomas, cortical dysplasias or even hamartomas.

Conditions

Benign Neuronal Desease

Outcome Measures

Primary Outcomes (3)

• Description of a new radiological entity on Spectroscopy : the MVNT (Multinodular and Vacuolating Neuronal Tumor)

  ratio of N-Acetylaspartate / Choline on Spectroscopy

  1 day

• Description of a new radiological entity on Spectroscopy : the MVNT (Multinodular and Vacuolating Neuronal Tumor)

  area under curve of the N-Acetylaspartate Spectroscopie

  1 day

• Description of a new radiological entity on Spectroscopy : : the MVNT (Multinodular and Vacuolating Neuronal Tumor)

  area under curve of choline Spectroscopie

  1 day

Interventions

cerebral MRI DEVICE

Patients who agree to participate in the study will perform a 3T multi-parametric MRI with advanced spectroscopic imaging techniques and standard protocol. A neurological consultation will take place during the inclusion visit as well as a questionnaire and a control MRI at 1 year and 2 years +/- 1 month.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patient supported for suspicion of MVNT

You may qualify if:

• Patient over 18 years old
• Suspicion of MVNT on an MRI: it is considered that it will be necessary at least the 2 major criteria associated with at least 1 minor criterion to enter the definition of suspicion of MVNT:
• Major criteria:
• Multinodular aspect in cluster
• High FLAIR hypersignal / T2
• Minor criteria:
• Absence of mass effect
• Hyposignal T1
• Center of the lesion in hypsignal FLAIR or T1 hypersignal
• Affiliate or beneficiary of a Social Security scheme
• Having received informed information about the study and consenting to participate in the study

You may not qualify if:

• Patient benefiting from a legal protection measure
• Pregnant or lactating woman
• Contraindication to MRI

Sponsors & Collaborators

• Fondation Ophtalmologique Adolphe de Rothschild: lead

Study Sites (7)

Groupe Hospitalier Pellegrin

Bordeaux, Bordeaux, 33076, France

Location

Fondation Adolphe de Rothschild

Paris, PARIS, 75019, France

Location

CHU Rennes

Rennes, Rennes, 35033, France

Location

CHU de Rouen

Rouen, Rouen, 76000, France

Location

Hôpital Pierre Paul Riquet, CHU Purpan

Toulouse, Toulouse, 31059, France

Location

Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France

Location

Hôpital Laennec

Saint-Herblain, 44800, France

Location

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 21, 2019
• First Posted: September 25, 2019
• Study Start: December 10, 2019
• Primary Completion: July 10, 2023
• Study Completion: July 10, 2025
• Last Updated: January 5, 2026

Record last verified: 2025-12

Locations

FR (7)